开云app官网登录入口网页版-官方正版

#存活期#

29篇内容 | 1234人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621208, encodeId=fa0a16212082e, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet Oncol：派姆单抗可显著延长复发或难治性经典霍奇金淋巴瘤患者的无进展存活期, objectType=article, longId=208561, objectId=5df320856197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5df320856197, replyNumber=0, likeNumber=64, createdTime=2021-03-19, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5df320856197, moduleTitle=Lancet Oncol：派姆单抗可显著延长复发或难治性经典霍奇金淋巴瘤患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5df320856197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621207, encodeId=29c6162120e56, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！, objectType=article, longId=207377, objectId=cb8020e3772b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb8020e3772b, replyNumber=0, likeNumber=59, createdTime=2021-02-22, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb8020e3772b, moduleTitle=Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cb8020e3772b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621206, encodeId=1628162120684, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：ATR抑制剂联合吉西他滨可延长铂耐药的高级别浆液性卵巢癌患者的无进展存活期, objectType=article, longId=196146, objectId=c66f19614679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66f19614679, replyNumber=0, likeNumber=0, createdTime=2020-06-21, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66f19614679, moduleTitle=Lancet oncol：ATR抑制剂联合吉西他滨可延长铂耐药的高级别浆液性卵巢癌患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c66f19614679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621205, encodeId=5803162120520, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, objectType=article, longId=193392, objectId=a9c11933925d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c11933925d, replyNumber=0, likeNumber=0, createdTime=2020-05-04, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c11933925d, moduleTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a9c11933925d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621204, encodeId=c2bd162120484, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期, objectType=article, longId=187899, objectId=b0bc18e89904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0bc18e89904, replyNumber=0, likeNumber=60, createdTime=2020-02-14, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0bc18e89904, moduleTitle=Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b0bc18e89904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621203, encodeId=f1661621203e2, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, objectType=article, longId=187111, objectId=646618e11101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646618e11101, replyNumber=0, likeNumber=107, createdTime=2020-02-03, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646618e11101, moduleTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=646618e11101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621202, encodeId=beac1621202a7, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, objectType=article, longId=164282, objectId=b041164282af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041164282af, replyNumber=0, likeNumber=63, createdTime=2019-04-16, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041164282af, moduleTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b041164282af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621201, encodeId=b39c162120170, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, objectType=article, longId=159703, objectId=2590159e03b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590159e03b3, replyNumber=0, likeNumber=85, createdTime=2019-02-11, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590159e03b3, moduleTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2590159e03b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621200, encodeId=56da162120061, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期, objectType=article, longId=159661, objectId=f84d15966103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f84d15966103, replyNumber=0, likeNumber=80, createdTime=2019-02-10, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f84d15966103, moduleTitle=Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f84d15966103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621199, encodeId=53e11621199ea, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：醋酸阿比特龙联合镭-223不能延长去势耐受性前列腺癌骨转移患者的无症状骨骼事件存活期, objectType=article, longId=159655, objectId=7e6a15965554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e6a15965554, replyNumber=0, likeNumber=77, createdTime=2019-02-10, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e6a15965554, moduleTitle=Lancet oncol：醋酸阿比特龙联合镭-223不能延长去势耐受性前列腺癌骨转移患者的无症状骨骼事件存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7e6a15965554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621198, encodeId=1027162119803, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Blood：血清TARC和IL10水平可指示霍奇金淋巴瘤患者的无进展存活期, objectType=article, longId=159556, objectId=52a61595562b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52a61595562b, replyNumber=0, likeNumber=0, createdTime=2019-02-08, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52a61595562b, moduleTitle=Blood：血清TARC和IL10水平可指示霍奇金淋巴瘤患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=52a61595562b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621197, encodeId=aba9162119e33, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Blood：Midostaurin可明显延长携带FLT3-ITD的急性髓系白血病患者的无进展存活期, objectType=article, longId=157647, objectId=a03815e64713, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a03815e64713, replyNumber=0, likeNumber=70, createdTime=2019-01-10, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a03815e64713, moduleTitle=Blood：Midostaurin可明显延长携带FLT3-ITD的急性髓系白血病患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a03815e64713)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621196, encodeId=1eac1621196a5, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：来曲唑维持治疗不能延长乳腺癌患者化疗后的无病存活期, objectType=article, longId=155382, objectId=c41215538266, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c41215538266, replyNumber=0, likeNumber=81, createdTime=2018-12-10, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c41215538266, moduleTitle=Lancet oncol：来曲唑维持治疗不能延长乳腺癌患者化疗后的无病存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c41215538266)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621195, encodeId=39e01621195d5, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响, objectType=article, longId=154529, objectId=b94515452947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94515452947, replyNumber=0, likeNumber=75, createdTime=2018-11-29, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94515452947, moduleTitle=Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b94515452947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621194, encodeId=90251621194aa, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期, objectType=article, longId=152211, objectId=8ea2152211a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ea2152211a2, replyNumber=0, likeNumber=59, createdTime=2018-10-31, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ea2152211a2, moduleTitle=Lancet oncol：VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8ea2152211a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621193, encodeId=bf4216211932a, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：三氟尿苷/替匹拉齐可明显提高晚期胃癌患者的总体存活期, objectType=article, longId=152063, objectId=5e8015206345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e8015206345, replyNumber=0, likeNumber=64, createdTime=2018-10-29, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e8015206345, moduleTitle=Lancet oncol：三氟尿苷/替匹拉齐可明显提高晚期胃癌患者的总体存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5e8015206345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621192, encodeId=c357162119246, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Blood：Duvelisib相比奥法木单抗可显着提高RR CLL/SLL患者的无进展存活期和总体缓解率, objectType=article, longId=150556, objectId=e527150556d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e527150556d6, replyNumber=0, likeNumber=55, createdTime=2018-10-09, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e527150556d6, moduleTitle=Blood：Duvelisib相比奥法木单抗可显着提高RR CLL/SLL患者的无进展存活期和总体缓解率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e527150556d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621191, encodeId=c2ad162119180, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet oncol：卡非佐米，每周一次，比每周两次，可显著延长复发性/难治性多发性骨髓瘤患者的无进展存活期, objectType=article, longId=139819, objectId=01201398198e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01201398198e, replyNumber=0, likeNumber=98, createdTime=2018-06-04, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01201398198e, moduleTitle=Lancet oncol：卡非佐米，每周一次，比每周两次，可显著延长复发性/难治性多发性骨髓瘤患者的无进展存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=01201398198e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621190, encodeId=a74e162119075, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Blood：博纳吐单抗用于复发性/难治性急性淋巴细胞白血病成年患者不仅可延长其存活期，还可改善其生活质量, objectType=article, longId=137632, objectId=d12113e632d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d12113e632d1, replyNumber=0, likeNumber=82, createdTime=2018-05-11, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d12113e632d1, moduleTitle=Blood：博纳吐单抗用于复发性/难治性急性淋巴细胞白血病成年患者不仅可延长其存活期，还可改善其生活质量, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d12113e632d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621189, encodeId=8d3116211897a, content=<a href='/topic/show?id=5ddb45343ef' target=_blank style='color:#2F92EE;'>#存活期#</a>, objectTitle=Lancet neurol：Riluzole（利鲁唑）可延长4期肌萎缩侧索硬化症患者存活期，但对早期患者无明显影响, objectType=article, longId=131823, objectId=327c13182330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327c13182330, replyNumber=0, likeNumber=76, createdTime=2018-03-10, rootId=0, userName=hukaixun, userId=498620204611, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327c13182330, moduleTitle=Lancet neurol：Riluzole（利鲁唑）可延长4期肌萎缩侧索硬化症患者存活期，但对早期患者无明显影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=327c13182330)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

存活期

2020-05-29

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet Oncol：派姆单抗可显著延长复发或难治性经典霍奇金淋巴瘤患者的无进展存活期

2021-03-19

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！

2021-02-22

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：ATR抑制剂联合吉西他滨可延长铂耐药的高级别浆液性卵巢癌患者的无进展存活期

2020-06-21

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期

2020-05-04

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期

2020-02-14

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期

2020-02-03

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期

2019-04-16

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期

2019-02-11

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期

2019-02-10

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：醋酸阿比特龙联合镭-223不能延长去势耐受性前列腺癌骨转移患者的无症状骨骼事件存活期

2019-02-10

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Blood：血清TARC和IL10水平可指示霍奇金淋巴瘤患者的无进展存活期

2019-02-08

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Blood：Midostaurin可明显延长携带FLT3-ITD的急性髓系白血病患者的无进展存活期

2019-01-10

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：来曲唑维持治疗不能延长乳腺癌患者化疗后的无病存活期

2018-12-10

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响

2018-11-29

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期

2018-10-31

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：三氟尿苷/替匹拉齐可明显提高晚期胃癌患者的总体存活期

2018-10-29

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Blood：Duvelisib相比奥法木单抗可显着提高RR CLL/SLL患者的无进展存活期和总体缓解率

2018-10-09

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet oncol：卡非佐米，每周一次，比每周两次，可显著延长复发性/难治性多发性骨髓瘤患者的无进展存活期

2018-06-04

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Blood：博纳吐单抗用于复发性/难治性急性淋巴细胞白血病成年患者不仅可延长其存活期，还可改善其生活质量

2018-05-11

hukaixun (审核中...)

前往app查看评论内容

#存活期#

Lancet neurol：Riluzole（利鲁唑）可延长4期肌萎缩侧索硬化症患者存活期，但对早期患者无明显影响

2018-03-10

科室
- - 订阅+
  - 更多科室
工具
服务